Marstacimab

马塔西单抗

Report date: 2026/05/08 20:02:52

Base Information

Drug NameMarstacimab
Drug Alias Name马塔西单抗marstacimab-hncqHYMPAVZI友瑞宁PF-6741086 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTissue factor pathway inhibitor inhibitors
TargetsTissue factor pathway inhibitor
Therapy Area/IndicationsHemorrhageHemophilia BHemophilia A
Global Approved IndicationsHemophilia BHemophilia A
Approved Indications in ChinaHemophilia BHemophilia A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/10/11
Country/TerritoryCzechiaBelgiumBulgaria +[38] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncPfizer Japan IncPfizer Europe Ma Eeig +[4] 
Inactive CompaniesPfizer Manufacturing Belgium Nv
Active IndicationsHemorrhageHemophilia BHemophilia A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG